1. Home
  2. BLRX vs AQMS Comparison

BLRX vs AQMS Comparison

Compare BLRX & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • AQMS
  • Stock Information
  • Founded
  • BLRX 2003
  • AQMS 2014
  • Country
  • BLRX Israel
  • AQMS United States
  • Employees
  • BLRX N/A
  • AQMS N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • AQMS Metal Fabrications
  • Sector
  • BLRX Health Care
  • AQMS Industrials
  • Exchange
  • BLRX Nasdaq
  • AQMS Nasdaq
  • Market Cap
  • BLRX 12.2M
  • AQMS 13.7M
  • IPO Year
  • BLRX 2011
  • AQMS 2015
  • Fundamental
  • Price
  • BLRX $2.92
  • AQMS $1.86
  • Analyst Decision
  • BLRX Strong Buy
  • AQMS Strong Buy
  • Analyst Count
  • BLRX 2
  • AQMS 2
  • Target Price
  • BLRX $53.00
  • AQMS $30.00
  • AVG Volume (30 Days)
  • BLRX 25.8K
  • AQMS 56.9K
  • Earning Date
  • BLRX 03-31-2025
  • AQMS 03-31-2025
  • Dividend Yield
  • BLRX N/A
  • AQMS N/A
  • EPS Growth
  • BLRX N/A
  • AQMS N/A
  • EPS
  • BLRX N/A
  • AQMS N/A
  • Revenue
  • BLRX $28,940,000.00
  • AQMS N/A
  • Revenue This Year
  • BLRX N/A
  • AQMS N/A
  • Revenue Next Year
  • BLRX N/A
  • AQMS N/A
  • P/E Ratio
  • BLRX N/A
  • AQMS N/A
  • Revenue Growth
  • BLRX 502.92
  • AQMS N/A
  • 52 Week Low
  • BLRX $2.85
  • AQMS $1.33
  • 52 Week High
  • BLRX $37.20
  • AQMS $14.10
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 34.77
  • AQMS 43.66
  • Support Level
  • BLRX $3.01
  • AQMS $1.89
  • Resistance Level
  • BLRX $3.61
  • AQMS $2.10
  • Average True Range (ATR)
  • BLRX 0.21
  • AQMS 0.16
  • MACD
  • BLRX 0.02
  • AQMS -0.01
  • Stochastic Oscillator
  • BLRX 9.21
  • AQMS 27.84

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About AQMS Aqua Metals Inc.

Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.

Share on Social Networks: